There are not a few experts who hope that the COVID pandemic will finally face the end of the road in 2022. The world has medications and other ways of tackling the coronavirus, thankfully.
We should also keep in mind that the monoclonal antibody treatment known as Evusheld, which was developed by AstraZeneca, can also be used against COVID as a preventive measure. It can be used by immunocompromised people or those who can’t get vaccinated because of medical reasons, according to DeseretNews.
Two injections are needed
Evusheld is administered through two injections containing the substance itself. The treatment was authorized back in December for emergency use by the FDA (Food and Drug Administration).
Patrizia Cavazzoni, M.D., director of the Center for Drug Evaluation and Research of the FDA, declared last year in December, as quoted by the federal agency’s website:
Vaccines have proven to be the best defense available against COVID-19. However, there are certain immune compromised individuals who may not mount an adequate immune response to COVID-19 vaccination, or those who have a history of severe adverse reactions to a COVID-19 vaccine and therefore cannot receive one and need an alternative prevention option,
Today’s action authorizes the use of the combination of two monoclonal antibodies to reduce the risk of developing COVID-19 in these individuals.
The highly-transmissible Omicron variant of COVID is significantly less predominant across the world than before. But even so, experts say that citizens should prepare for new outbreaks.
Abraar Karan, an infectious disease physician from Stanford University, stated as The Guardian quotes:
Once we have another variant, whenever that may be, the amount of spread from that variant will depend on what kind of preparedness we do now. What are we doing to make schools, workplaces and public spaces more safe?
